Neoss ® Group Receives EU MDR Certifications for Implants and Abutments

Neoss Group, a leading innovator in dental implant solutions, is proud to announce that it has received EU Medical Device Regulation (MDR) certification by its Notified Body, the BSI Group, the Netherlands B.V. for its implants and abutments. This certification adds to the previous MDR certification of Neoss’ Quality Management System and Class I Reusable instruments that was granted in 2022. This signifies that Neoss Group’s Quality Management System and its implants and abutments meet the requirements of the new MDR implemented by the European Union.

“MDR is one of the most thorough medical device regulations in the world. It ensures that medical devices meet the highest standards. The certification shows that we are in the forefront of implant solutions and that we provide best in class quality and care to our customers and their patients.” Dr. Robert Gottlander, President and CEO of the Neoss Group.

This once again demonstrates that Neoss Group is at the forefront of their commitment to ensuring that their products adhere to the highest standards for the benefit of their customers and their patients. They are also one of the first companies in the dental device field to achieve MDR certification for their products.

“The MDR certification gives Neoss the freedom to continue innovating intelligent solutions that benefit our customer and their patients. The MDR certification also shows that Neoss products are backed with clinical evidence of the highest standard and ensures that the products are continuously monitored in post-market studies.” Mr. Fredrik Engman, CTO and co-founder of Neoss.”

The new EU Medical Devices Regulation 2017/745 (MDR) replaces the former European Medical Device Directive 93/42/EEC (MDD), and brings EU legislation into line with technical advances, changes in medical science and progress in law-making. The new MDR regulation creates a robust, transparent, and sustainable regulatory framework, improving clinical safety and creating fair market access for manufacturers and healthcare professionals. The new MDR regulation contains a series of important improvements including establishing a comprehensive and accessible EU database on medical devices with a device traceability system based on a unique device identification.

SourceNeoss®

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”